Cargando…

Combinational Use of Antiplatelet Medication Sarpogrelate with Therapeutic Drug Rosuvastatin in Treating High-Cholesterol Diet-Induced Chronic Kidney Disease in ApoE-Deficient Mice

A number of metabolic disorders, including hyperlipidemia, potentially cause chronic kidney disease (CKD), one of their major chronic complications and comorbidities. Rosuvastatin is one of the widely used antiatherogenic drugs among hyperlipidemic patients. Meanwhile, sarpogrelate is not only a 5-h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Jingyi, Pei, Zuowei, Yu, Meng, Li, Xiang, Wang, Lu, Lin, Yichen, Chen, Xinyan, Liu, Xiaodan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537702/ https://www.ncbi.nlm.nih.gov/pubmed/33029491 http://dx.doi.org/10.1155/2020/1809326

Ejemplares similares

Sarpogrelate and rosuvastatin synergistically ameliorate aortic damage induced by hyperlipidemia in apolipoprotein E-deficient mice
por: Liu, Hongyang, et al.
Publicado: (2020)

Beneficial Effects of Sarpogrelate and Rosuvastatin in High Fat Diet/Streptozotocin-Induced Nephropathy in Mice
por: Kim, Dong-hyun, et al.
Publicado: (2016)

Suppression of high lipid diet induced by atherosclerosis sarpogrelate
por: Xu, Yan-Jun, et al.
Publicado: (2012)

Sarpogrelate Based Triple Antiplatelet Therapy Improved Left Ventricular Systolic Function in Acute Myocardial Infarction: Retrospective Study
por: Choi, Jae Hyuk, et al.
Publicado: (2017)

Aspirination of α-Aminoalcohol (Sarpogrelate M1)
por: Park, Sunhwa, et al.
Publicado: (2016)

Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results
por: Chen, Yue-Xin, et al.
Publicado: (2015)

Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice
por: Park, Kyung-Yeon, et al.
Publicado: (2016)

The Role of ERK1/2 Activation in Sarpogrelate-Mediated Neuroprotection
por: Ku, Cristy A., et al.
Publicado: (2018)

Total cholesterol content of erythrocyte membranes is associated with the severity of coronary artery disease and the therapeutic effect of rosuvastatin
por: Zhong, Yucheng, et al.
Publicado: (2012)

Novel usage of sarpogrelate hydrochloride in patients with allergy-related variant angina
por: Noma, Kensuke, et al.
Publicado: (2012)

Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database
por: Noh, Yoojin, et al.
Publicado: (2016)

Rosuvastatin alleviates high-salt and cholesterol diet-induced cognitive impairment in rats via Nrf2–ARE pathway
por: Husain, Ibraheem, et al.
Publicado: (2018)

Effect of sarpogrelate treatment on the prognosis after endovascular therapy for critical limb ischemia
por: Takahara, Mitsuyoshi, et al.
Publicado: (2013)

Therapeutic activity of sarpogrelate and dopamine D(2) receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes
por: Fouad Shalaby, Mohammed Ahmed, et al.
Publicado: (2021)

Safety and efficacy of short-term dual antiplatelet therapy combined with intensive rosuvastatin in acute ischemic stroke
por: Deng, Ting, et al.
Publicado: (2023)

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin
por: Kroonen, Marjolein Y. A. M., et al.
Publicado: (2019)

The Prevention of Contrast Induced Nephropathy by Sarpogrelate: a Prospective Randomized Controlled Clinical Trial
por: Ki, You-Jeong, et al.
Publicado: (2019)

Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe
por: Yamazaki, Daisuke, et al.
Publicado: (2013)

Arginase Activities and Global Arginine Bioavailability in Wild-Type and ApoE-Deficient Mice: Responses to High Fat and High Cholesterol Diets
por: Erdely, Aaron, et al.
Publicado: (2010)

Effects of sarpogrelate, a 5-hydroxytriptamine 2A receptor antagonist on endotoxin shock in rats
por: Nishiyama, T
Publicado: (2005)

Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans
por: Min, Jee Sun, et al.
Publicado: (2016)

Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials
por: Lu, Yunxin, et al.
Publicado: (2019)

Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats
por: Fouad Shalaby, Mohammed, et al.
Publicado: (2021)

Rosuvastatin Decreases the Formation of Neointima by Increasing Apo J, Reducing Restenosis after Balloon Injury in Rats
por: Dourado, Paulo Magno Martins
Publicado: (2018)

The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial
por: Park, Kyungil, et al.
Publicado: (2010)

Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering
por: Yu, Pei, et al.
Publicado: (2018)

Dietary Ellagic Acid Ameliorates Functionality of Reverse Cholesterol Transport in apoE-Deficient Mice
por: Park, Sin-Hye, et al.
Publicado: (2022)

Comparison of Apolipoprotein (apoB/apoA-I) and Lipoprotein (Total Cholesterol/HDL) Ratio Determinants. Focus on Obesity, Diet and Alcohol Intake
por: Tognon, Gianluca, et al.
Publicado: (2012)

Evaluation and subgroup analysis of the efficacy and safety of intensive rosuvastatin therapy combined with dual antiplatelet therapy in patients with acute ischemic stroke
por: Deng, Ting, et al.
Publicado: (2022)

A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol
por: Niedzielski, Mateusz, et al.
Publicado: (2021)

Sarpogrelate hydrochloride ameliorates diabetic nephropathy associated with inhibition of macrophage activity and inflammatory reaction in db/db mice
por: Lee, Eun Soo, et al.
Publicado: (2017)

A Western-Fed Diet Increases Plasma HDL and LDL-Cholesterol Levels in ApoD–/– Mice
por: Ali, Kamilah, et al.
Publicado: (2014)

LCAT, ApoD, and ApoA1 Expression and Review of Cholesterol Deposition in the Cornea
por: Flores, Rhonda, et al.
Publicado: (2019)

Rosuvastatin prevents proteinuria and renal inflammation in nitric oxide–deficient rats
por: Girardi, José Marcos, et al.
Publicado: (2011)

LXRα is uniquely required for maximal reverse cholesterol transport and atheroprotection in ApoE-deficient mice
por: Hong, Cynthia, et al.
Publicado: (2012)

Saringosterol from Sargassum fusiforme Modulates Cholesterol Metabolism and Alleviates Atherosclerosis in ApoE-Deficient Mice
por: Yan, Ying, et al.
Publicado: (2021)

APOE deficiency impacts neural differentiation and cholesterol biosynthesis in human iPSC-derived cerebral organoids
por: Zhao, Jing, et al.
Publicado: (2023)

Diet in Stroke: Beyond Antiplatelets and Statins
por: James, Joe
Publicado: (2019)

Effects of high-fat diet and Apoe deficiency on retinal structure and function in mice
por: Cao, Xiupeng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_943ln8t47kgilgl5v1hf72hkjt